HK1206266A1 - 用於預防和治療神經病的方法和組合物 - Google Patents

用於預防和治療神經病的方法和組合物

Info

Publication number
HK1206266A1
HK1206266A1 HK15106955.3A HK15106955A HK1206266A1 HK 1206266 A1 HK1206266 A1 HK 1206266A1 HK 15106955 A HK15106955 A HK 15106955A HK 1206266 A1 HK1206266 A1 HK 1206266A1
Authority
HK
Hong Kong
Prior art keywords
prevention
compositions
methods
treatment neuropathy
neuropathy
Prior art date
Application number
HK15106955.3A
Other languages
English (en)
Inventor
Travis D Wilson
Original Assignee
Stealth Peptides Internat Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides Internat Inc filed Critical Stealth Peptides Internat Inc
Publication of HK1206266A1 publication Critical patent/HK1206266A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15106955.3A 2012-03-30 2015-07-21 用於預防和治療神經病的方法和組合物 HK1206266A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261618428P 2012-03-30 2012-03-30
PCT/US2013/034647 WO2013149172A1 (en) 2012-03-30 2013-03-29 Methods and compositions for the prevention and treatment neuropathy

Publications (1)

Publication Number Publication Date
HK1206266A1 true HK1206266A1 (zh) 2016-01-08

Family

ID=49261299

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106955.3A HK1206266A1 (zh) 2012-03-30 2015-07-21 用於預防和治療神經病的方法和組合物

Country Status (9)

Country Link
US (4) US9636378B2 (zh)
EP (3) EP2830644B1 (zh)
JP (2) JP6317324B2 (zh)
CN (2) CN107320712A (zh)
AU (2) AU2013237827B2 (zh)
CA (1) CA2869080C (zh)
DK (1) DK2830644T3 (zh)
HK (1) HK1206266A1 (zh)
WO (1) WO2013149172A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2830644T3 (en) * 2012-03-30 2017-02-27 Stealth Peptides Int Inc Methods and Preparations for the Prevention and Treatment of Neuropathy
JP2019523260A (ja) 2016-04-11 2019-08-22 カーノット， エルエルシー キラルペプチド
US10961273B2 (en) 2016-08-16 2021-03-30 Stealth Biotherapeutics Corp. N-carboxyanhydride-based-scale synthesis of elamipretide
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
CN112961249B (zh) * 2021-02-25 2023-08-04 兰州大学 一类基于阿片肽和大麻肽的双功能肽及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5913318A (ja) 1982-07-13 1984-01-24 株式会社村田製作所 電子部品の製造方法
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
AU2005208821B8 (en) * 2003-02-04 2010-10-14 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3479838A1 (en) * 2003-02-04 2019-05-08 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
SI1599216T1 (sl) * 2003-02-04 2014-02-28 Cornell Research Foundation, Inc. Postopek za preprečevanje mitohondrijskega permeabilnostnega prehoda
WO2007035640A2 (en) * 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
JP5453320B2 (ja) * 2008-02-07 2014-03-26 コーネル ユニヴァーシティー インスリン抵抗性を防止または処置するための方法
US8143219B2 (en) * 2008-02-26 2012-03-27 Cornell University Methods for prevention and treatment of acute renal injury
US20100331265A1 (en) * 2009-03-20 2010-12-30 Tompkins Ronald G Methods for the prevention and treatment of burn injuries and secondary complications
EP2464371B1 (en) * 2009-08-12 2016-03-16 Cornell University Methods for preventing or treating metabolic syndrome
EP3524256A1 (en) * 2009-08-24 2019-08-14 Stealth Peptides International, Inc. Methods and copositions for preventing or treating opthalmic conditions
JP2013506696A (ja) * 2009-10-05 2013-02-28 コーネル ユニヴァーシティー 心不全の予防又は処置の方法
EP2915540A1 (en) * 2009-12-31 2015-09-09 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
AU2010339410A1 (en) * 2009-12-31 2012-07-19 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
US20120329730A1 (en) * 2010-01-25 2012-12-27 Institut De Recherches Cliniques De Montreal Aromatic-cationic peptides and uses of same
JP2013521231A (ja) * 2010-02-26 2013-06-10 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
EP3210615A1 (en) * 2010-03-15 2017-08-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
WO2012006569A1 (en) * 2010-07-09 2012-01-12 Stealth Peptides International, Inc. Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
US20120083452A1 (en) * 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
KR101351432B1 (ko) 2011-12-27 2014-01-15 에스케이씨 주식회사 초미세 발포 폴리우레탄 탄성체의 제조방법
DK2830644T3 (en) * 2012-03-30 2017-02-27 Stealth Peptides Int Inc Methods and Preparations for the Prevention and Treatment of Neuropathy

Also Published As

Publication number Publication date
CN107320712A (zh) 2017-11-07
AU2017265013A1 (en) 2017-12-07
US20190343913A1 (en) 2019-11-14
CN104271146A (zh) 2015-01-07
US20200397850A1 (en) 2020-12-24
EP3406257A1 (en) 2018-11-28
AU2017265013B2 (en) 2019-04-18
US20220296672A1 (en) 2022-09-22
US9636378B2 (en) 2017-05-02
US20150087595A1 (en) 2015-03-26
AU2017265013B9 (en) 2019-05-02
EP3170506A1 (en) 2017-05-24
US20170340695A1 (en) 2017-11-30
WO2013149172A1 (en) 2013-10-03
CA2869080A1 (en) 2013-10-03
DK2830644T3 (en) 2017-02-27
CA2869080C (en) 2020-09-01
US10646539B2 (en) 2020-05-12
EP2830644A4 (en) 2015-10-21
US10279008B2 (en) 2019-05-07
EP2830644B1 (en) 2016-11-16
AU2013237827A1 (en) 2014-10-16
AU2013237827B2 (en) 2017-12-14
EP3170506B1 (en) 2018-05-16
JP2015512420A (ja) 2015-04-27
JP6317324B2 (ja) 2018-04-25
EP2830644A1 (en) 2015-02-04
JP2018123143A (ja) 2018-08-09
EP3406257B1 (en) 2020-04-22

Similar Documents

Publication Publication Date Title
IL266582A (en) Compositions and methods for the treatment of hemoglobinopathies
HK1214521A1 (zh) 用於治療蛋白質病的組合物和方法
HK1216009A1 (zh) 前列環素組合物及其使用方法
EP2861256A4 (en) COMPOSITIONS FOR THE TREATMENT OF CANCER AND METHODS FOR PREPARING THE SAME
HK1251796A1 (zh) 治療糖尿病的方法和組合物
EP2875359A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLISM SYNDROME DISEASES
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
HK1204988A1 (zh) 用於預防或治療眼科病狀的方法和組合物
HK1209633A1 (zh) 治療糖尿病的組合物和方法
EP2897613A4 (en) TREATMENT COMPOSITIONS
HK1216250A1 (zh) '- '-羥基-二氫麥角胺化合物及組合物
HK1206266A1 (zh) 用於預防和治療神經病的方法和組合物
GB201315350D0 (en) Methods and compositions
HK1212366A1 (zh) 紡織品處理化合物和組合物
GB201315347D0 (en) Methods and compositions
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
EP2931280A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING CNKSR1
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
EP2834635A4 (en) COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR
IL235312A0 (en) Taxane compounds, preparations and methods
EP2800763A4 (en) COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
GB201222736D0 (en) Composition and process